参考資料５ 農薬評価書 メタアルデヒド（食品安全委員会資料）
|
|
|
- まさとし たみや
- 5 years ago
- Views:
Transcription
1
2 (1) 8 (2) 9 (3) 9 (4) 10 (5) (1) 11 (2) 11 (3) 11 (4) (1) 12 (2) 12 (3) (1)
3 (2) (3) 6 18 (4) (1) 1 19 (2) 2 / 19 (3) (1) 2 22 (2) 24 (3) (1) in vivo 25 (2) 26 (3)
4 * ** * **
5 * * * ** * **
6 IUPAC2,4,6,8- -1,3,5,7-- / 2 2 / 2.2mg/kg / mg/kg /ADI 5
7 metaldehydeiso IUPAC 2,4,6,8--1,3,5,7-- 2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclo-octane CAS (No ) 2,4,6,8--1,3,5,7-2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane C8H16O
8 C 14 C- 1 SD 5 14 C- 10 mg/kg 100 mg/kg TAR % % 7898%TAR 9495% %TAR Cmax µg/ml T1/ (24.5), (9.32), (8.36), (7.59), (7.13), (6.86), (2.04),(1.69),(1.69), (1.18),(0.95),(0.89),(0.88), (6.79), (6.34), (5.63), (5.33), (5.06), (4.67), (0.83),(0.82),(0.76),(0.75), (0.67),(0.66),(0.55), (4.64),(4.46) (0.54),(0.50),(0.46) (31.0),(8.29), (7.93), (2.13), (2.03), (1.87), (7.83),(7.75), (7.60), (7.07), (6.72), (6.17), (6.09) (1.79), (1.54), (1.34), (1.29),(1.00),(0.91),(0.81), (0.72),(0.64),(0.57),(0.51), (0.43) (38.9), (28.9), (22.3) (21.5), (12.2), (11.3),(11.3),(11.0),(10.9), (8.96),(7.97),(7.93),(6.96), (6.95),(6.00),(5.88),(5.25) 7
9 2 3 (24.9), (24.1), (15.7), (14.5), (12.5),(12.5), (10.9),(10.9),(10.7),(7.23), (6.76),(6.39),(6.28),(6.20), (5.81),(5.64),(5.09) (2.07), (1.89), (1.76), (1.48), (1.47), (1.34), (1.23),(1.18),(1.18),(1.01), (0.89),(0.72),(0.71),(0.65), (0.63),(0.58) (2.42), (1.83), (1.76), (1.52),(1.23),(1.19),(1.02), (1.01), (0.96), (0.94), (0.75),(0.66),(0.63),(0.56), (0.52), (0.50), (0.45), (0.39) Cmax µg/ml µg /ml T1/ µg /ml µg /ml C- 4 % 1.5 kg ai/ha cm mg/kg mg/kg 1 8
10 cm) 0.65 mg/kg mg/kg % 75.1TAR %TAR C- 4 % 15 kg ai/ha remolacha cm mg/kg % 13% C- 1000mg/kg 5 kg ai/ha TRR mg/kg TRR mg/kg 92%TRR - 43% 26% 14 C 83%TRR 19%TRR 17%TRR 10%TRR 9
11 5 14 C- 15kg ai/ha 0.46%TAR 80 % 6.61 mg/kg (25.4%TRR) 133 mg/kg (67.8%TRR) 0.06%TAR 1.48 mg/kg (61.4%TRR) 1.0 mg/kg (14.0%TRR) 4.92 mg/kg(21.9%trr) mg/kg (2.8%TRR) mg/kg (1.7%TRR) mg/kg (2.6%TRR) % mg/kg (41.8%TRR) mg/kg mg/kg 14 C- 8.3% mg/kg C kg ai/ha lechuga cm mg/kg 90% 22% 10
12 % ( 7 14 C µg/g % KOH 87% 64%TARKOH 5.3%TAR %TAR % % C- 4.8 µg/g TAR C µg/g
13 %TAR KOH 8.31%TAR 2.06%TAR 10.4TAR 6673TAR KOH TAR %TAR %TAR [ Koc % 11 ph 4 ph7 ph9 5 µg/ml ph ph 7 9 ( 12) 14 C- ph5 ph7 Tris ph7 HEPES ph9 23 µg/ml(ph5)25 µg/ml(ph7,tris)23.1 µg/ml(ph7, HEPES)25.5 µg/ml(ph9)
14 14 C- ph7.0 HEPES 32 µg/ml 28 µg/ml W/m nm mg /kg 105 D mg ai/kg mg/kg 200 SC 4 2.1kg ai/ha 3 G kg ai/ha 8 G 1 6 kg ai/ha 1 DSCG
15 kg ai/ha () (mg/kg) PHI () <0.05 <0.05 <0.05 <0.05 aiphi 4 20 / mg/kg 3 0,10,30, ,10,30, 100 0,3,10,30, 100 0,30, ,10,30, 100,300 mg/kg mg/kg mg/kg 100 mg/kg 10mg/kg 30mg/kg 12 30mg/kg 300mg/kg 6 0, 30,100,
16 0,10,30, ,10,30, , 30, PTAPTT 100,300 - SD BKW SD LD50mg/kg SD SD BKW SD 422
17 SD LC50mg/L SD NZW 2830 Hartley Buehler 31 SD ppm ppm 750 ppm 2500 ppm mg/kg / ppm 250 ppm18.9 mg/kg /22.5 mg/kg / ppm
18 750 ppm 250 ppm ICR ppm ppm 300 ppm 1000 ppm 3000 ppm ppm mg/kg / ppm 100ppm19.0 mg/kg /23.7 mg/kg / ppm 5 / 3000 ppm 3000ppm 10000ppm 1000 ppm 300ppm 100ppm 17
19 mg/kg / mg/kg / 60 mg/kg / 90 mg/kg / mg/kg / mg/kg / 60 mg/kg / 20.2 mg/kg / 86.7 mg/kg / 3453 SD ppm ppm 500 ppm 2500 ppm mg/kg / ppm ppm 100 ppm7 mg/kg /8 mg/kg / ppm 1 18
20 500 ppm 100 ppm mg/kg / mg/kg / 10 mg/kg / mg/kg / HbMCVMCHAPTT ALPGGT HbHtMCH ALPGGT 30mg/kg / 10mg/kg / SD ppm 14 2 / 50 ppm 1000 ppm 5000 ppm mg/kg / ppm 19
21 50 ppm2.2 mg/kg /3.0 mg/kg / ppm MCVMCH TPGlob A/G 1000 ppm T.Chol 50 ppm ppm ppm ppm [ ] [ ] 8 [ ] 13 [ ] 11 [ ] [666- [575- [609- [ ] 728] 722] 728] 1 4 [ ] 7 [ ] 11 [ ] 11 [ ] 9 [ ] 13 [ ] [ [428- [ ] 429] 686] [484- [708] 485]
22 3 2 1 [477- [435- [468] 666] 624] [349- [548- [ ] 609] 723] [505- [421- [ ] 708] 729] [ ] [ ] [ ] [ ] [ ] [ ] [646- [635- [564- [358- [714] [587] 691] 646] 663] 582] [630] [ ] 3 [ ] 6 [ ] [ ] [ ] 3 [ ] 1 [ ] 1 [ ] 5 [ ] 11 [ ] 11 [ ] [ ] [ ] [ ] 3 1 [609- [565] 678] [603- [ ] 576] ppm * * 0 Fisher 2 p< ppm
23 0 6 a 20 bd 38 bd c bd 5 Fisher a 1 p<0.05b: 1 p<0.01 c: 2 p<0.05d 2 p<0.01 ICR ppm ppm 100 ppm 300 ppm mg/kg / ppm 300 ppm 10% 3 20 ppm * 3 % * 5.0 Fisher * 1 p< ppm 100 ppm16 mg/kg /20 mg/kg / 3853 SD ppm 3 ICRCD / 7.2% %/ 22
24 ppm 1000 ppm 2000 ppm P (mg/kg /) F ppm F ppm F ppm P 1 P F ppm F ppmp 69 mg/kg /P 81 mg/kg /F1 65 mg/kg /F1 81 mg/kg / 2000 ppm 2000 ppm 1000 ppmf1 138mg/kg /F1 81mg/kg /F2 134mg/kg /F2 81mg/kg / PF1 F1F ppm / // 1000 ppm 2000 ppm 1000 ppm 23
25 SD mg/kg / 150 mg/kg /6 ) 150 mg/kg / 75 mg/kg / 150 mg/kg / 4053 NZW mg/kg / 80 mg/kg / 41 DNA CHO in vitro DNA E.coli WP2, WP67 uvra, pola, CM871(uvrA, reca, lexa) µg/ +/S9 S. typhimurium TA98, TA100, TA1535, µg/ TA1537, TA1538 +/S9 432 µg/ +/S9 24
26 S. typhimurium TA98, TA100, µg/ TA1535,TA1537 +/S9 E.coli WP2uvrA µg/mls9 L5178Y µg/mls µg/mls9 (+/S9) CHO µg/mls9 in vivo BKW mg/kg 1 5 +/S9 in vivo Fischer 15 9 N- DEN(200 mg/kg ppm 24 PB 5000 ppm DEN ppm ppm 1000 ppm 5000 ppm mg/kg / ppm DEN PB 5000 ppm mm -S-GST-P) GST-P DEN DEN DEN 25
27 5000ppm GST-P 1000ppm DEN PB 5000 ppm355 mg/kg / 1000 ppm73 mg/kg / ppm GLP 2 /5000 ppm ppm ppm (ppm) /28 641/ / / / / / / ppm PF1 F / ppm F1 F2 1 3/ pm 1000 ppm 49 GLP
28 (mg/kg /) (mg/kg /) / P 69 P F1 65 F
29 mg/kg mg/kg PTAPTT
30 ph ph LD mg/kg mg/kg LD50 422mg/kg LD mg/kg LC50 15 mg/l 7 mg/kg / 19.0 mg/kg / 20.2 mg/kg / 2.2 mg/kg / 16 mg/kg / 10 mg/kg / 355 mg/kg / 65 mg/kg / 81mg/kg / / 2000 ppm/ 29
31 ppm MAO GABA NA5HT GABA 75 mg/kg / 150 mg/kg / 80 mg/kg / DNA CHO ( 28 4 mg/kg / mg/kg / /
32 2 P 69 P 138 P 81 P 160 F1 65 F1 134 F1 81 F1 164 F1 138 F1 F1 81 F1 160 F2 134 F2 F2 81 F / 2.2 mg/kg / mg/kg /ADI ADI mg/kg / ADI / mg/kg /
33 32 1 5HT 5- ai A/G / ALP APTT Cmax DEN GABA γ- GGT γ- =γ γ-gtp Glob GST-P -S- Hb Ht MCHC MCH MCV MAO NA PB PHI PT T1/2 TAR T.Chol TP TRR
34 URLhttp:// 2 GLP Biological Test Center GLP Biological Test Center GLP PTRL East, Inc GLP GLP GLP PTRL East, Inc GLP Analytical Biochemistry Laboratories GLP Battelle Europe GLP Analytical Biochemistry Laboratories GLP Analytical Bio-chemistry Laboratories Inc GLP Analytical Bio-chemistry Laboratories Inc GLP SafePharm Laboratories Institut fur Biologishe Forschung Institut fur Biologishe Forschung GLP SafePharm Laboratories Institut fur Biologishe Forschung Huntingdon Research Centre
35 27 Huntingdon Research Centre GLP SafePharm Laboratories Institut fur Biologishe Forshung Hazleton Laboratories GLP Consumer Product Testing GLP SafePharm Laboratories GLP Bushy Run Research Center Laboratorium fur Pharmakologi und Toxikologie GLP SafePharm Laboratories GLP Laboratory of Pharmacology and Toxicology /GLP Bushy Run Research Center GLP Bushy Run Research Center GLP Bushy Run Research Center GLP Bushy Run Research Center GLP Bushy Run Research Center DNA GLP Life Science Research GLP SafePharm Laboratories GLP NOTOX C.V CHO in vitro GLP NOTOX C.V GLP SafePharm Laboratories
36 48 in vivo GLP H.G.Verschuuren et al., LONG-TERM TOXICICITY AND REPRODUCTION STUDIES WITH METALDEHYDE IN RATS. Toxicology, 4(1975) URL (URLhttp:// URL nouyaku/n-dai7/index.html URLhttp:// n-dai35/index.html b URL URL URL URL 35
untitled
1 2 1 2002 8 1 2003 11 1 152 2003 11 2 21 53 2003 12 24 4 54 2004 3 22 55 2004 4 9 56 2004 4 15 41 2004 4 15 2004 5 12 2004 5 19 2004 5 20 5 2004 12 16 58 2 2005 1 25 2005 8 23 5962 2005 8 26 2005 9 1
untitled
2001 4 26 2003 5 22 2004 7 12 2004 7 15 54 2004 7 21 14 2004 9 16 62 IUPAC4--2--N,N --5-p --1-2 17.07 mg/kg / 100 0.17 mg/kg /ADI cyazofamidiso IUPAC 4--2--N,N- -5-p --1-4-chloro-2-cyano-N,N -dimethyl-5-p
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
まえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
CAS H 3 C C CH 2 C 9 H tert d = hpa
1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
040202PC用.doc
15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
- 108 -
3-107- - 108 - 3.1 3.1.1 3.1.2 3.1.2.1 5 LD50 LC50 ATE 3.1.1 1 2 3 4 5 (mg kg ) 5 50 300 2000 5000 a (mg kg ) 50 200 1000 2000 a (ppm) 100 500 2500 5000 a b mg 0.5 2.0 10 20 a b c d 0.05 0.5 1.0 5 (mg
CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa
1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
後期化学_01_濃度
2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml
,161 t 9,753 t 2,408 t LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum 6 3 Selenastrum h, Sb
1 20017 1543 CAS 1309644 125 Sb 2 O 3 291.52 1 99 1. 2 655 1,425 2 2 2 3 5.2 5.67 2 2 2. 10 12,161 t 9,753 t 2,408 t 4 3. 1 2 3 4. LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4
2-1 9628 31307 CAS 117817 2- O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O 4 390.56 CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) 3 1 99 % 2- ABHT 1. 2-55 3 3, 4 386 171 350 6 0.1 % d 20 4 0.9861 4 13.48 0.30410-4 Pa 2.2810-7
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
ver5.1 HS 1. ALPHA LIPOIC ACID () S S COOH HS 1. α - SH COOH - ( 1) CoA -( 2)- - --P80 (--WSP8-L1-WSPC8 -LC1) - 1
ORYZA OIL & FAT CHEMICAL CO., LTD. ALPHA LIPOIC ACID --P () --P80 () --WSP8 () --L1 () --PC () --PC80 () --WSPC8 () --LC1 () ver. 5.1HS ver5.1 HS 1. ALPHA LIPOIC ACID 16 3 31 0331009 - () 19 5 24 0524001
untitled
ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
橡三酸化二アンチモン.PDF
1 2001 7 1 543( ) CAS 1309 64 4 1 25 ( ) Sb 2 O 3 291.52 1) 99 1. 2) 655 3) 1,425 3) ( ) 2) ( ) 2) ( ) 2) 5.2 ( ) 5.67 ( ) 3) 2) 2. 10 12,161 t ( 9,753 t 2,408 t) 4 2 1) 3. 1) 2) 3) 4. Selenastrum capricornutum
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
橡フタル酸ブチルベンジル.PDF
1 97 7 3 1312 CAS 85 68 7 O BBP 1, 2- C 19 H 20 O 4 312.4 C C O O O (CH 2 ) 3 1 99.9 % 1. 2-35 3 2, 3 370 3, 4 199 d 25 4 1.117 2 10.8 = 1 5 1.15 10-3 Pa 8.6 10-6 mmhg 20 5 253 Pa 1.9 mmhg 200 5 log Pow
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
橡アジポニトリル.PDF
1 200117 21512( ) CAS 111693 110( ) 1,4- NC(CH 2 ) 4 CN C 6 H 8 N 2 108.14 1) 99 2-1. 2) 1 2) 295 2) 159(c.c.) 3) 550 3) 1.7-4.9 vol % ( ) 3) d 20 0.965 2) 3.73 ( = 1) 4 0.3 Pa (0.002 mmhg) (20) 2) log
Microsoft Word - 14_LCMS_アクリルアミド
3--2-3-Iodo-2-propynyl butylcarbamate (IPBC) Carbamic acid, butyl-, 3-iodo-2-propynyl ester Iodocarb CAS 55406-53-6 C 8 H 12 NO 2 I C (g/cm 3 ) (mmhg) log P ow 281.09 (280.9910) 64 68 1.51 1.57 (20 C)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
untitled
-1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86
32 100 34 51 16,300
32 100 34 51 16,300 - 7 - - 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 1 3 3 5 5 B 6 2 2 4 4 6 10 - - 8 - - - 9 - 20 80 1/3 - - 10 - 0.7 0.9kg 21 147 70-11 - - 50 10cm 50 100 30cm kg 100
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
20 57
56 20 57 58 59 12 60 ph 61 62 CCA 63 64 ( 1) 700 7.5 86% 54 17 71 2) 700 6.8 86% 50 15 65 3) 600 700 5.7 84% 36 14 50 550 650 4.2 80% 21 6 27 40 500 3.6 78% 16 7 23 3.6 78% 16 7 23 400 700 4.0 78% 18 7
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
90 27 1 29 ( ) 27 4 26 ( ) 27 4 29 ( ) 4 27 3 30 ( ) 1 30 4 27 4 8 ( ) 16 ( ) 9 P2 3 301 27 4 14 ( ) 15 ( ) 9 5 27 4 21 ( ) 4 27 4 21 ( ) 8 30 5 27 4 23 ( ) 5 10 11 12 13 4 3 4 14 27 4 23 ( 27 4 25 ( )
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
ボトックス注用
2018 5 21 2017 1220 5 8 7 1 2 2 9 50 100 22100AMX00488 22100AMX00489 2009 9 2009 9 2009 2 1997 4 2016 6 2018 5 1989 12 1A 2 1 2 3 2 4 5) 1 100 1 2 3 4 A 1 50 50 0 45mg 0 25mg 100 100 0 9mg 0 5mg A 1 4mL
ケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
untitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
緑化計画作成の手引き 26年4月版
http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic
0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
（配布資料２）【食品安全委員会】滋賀県食の安全安心シンポジウム
1 2 3 2003(Codex, FAO/WHO) 4 ( ) 5 6 ( ) 1 2 7 ADI MRL 8 9 10 11 1cm 12 600-2,700μg RAE/ 13 14 15 16 17 18 19 20 21 22 23 24 25 26 100 100 1 ADI 1 27 ADI NOAEL 28 mg/kg / mg/kg / 29 30 /kg / 24 23 31 32
98-02.PDF
1 982 2207 CAS 67630 2- H 3 C H 3 C CH OH C 3 H 8 O 60.10 1 99.9 % n- 1. 2-88.5 3 82.5 3 11.7c.c. 455 4 212 d 20 4 0.78505 3 2.1 = 1 4 4.4 kpa 33 mmhg20 4 log Pow0.05 0.07 5 m/z45, 1.0 43 0.19 27 0.17
2902 Shiraki et al., Aerosol and Air Quality Research, 17: , 2017 McLean, 1961; Schulman and Kilbourne, 1962; Moser et al., 1979; Knight, 198
PM 2.5 PM 2.5 UV-LED UV-LED 375 nm TiO 2 TiO 2 5 10 1 cm 200 5 ppm 9012.4 µmol h -1 1:2 2 25.43 µmol h -1 1 m 3 20 ppm 8 60 779 L A/PR/8/1934 H1N1 RNA 7 28 RNA PM2.5 TiO2 PM 2.5 VOC Hess et al., 2016;
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
エコリシン点眼液/眼軟膏インタビューフォーム
2011 11 4 871319 1mL 5mg 5mg15 1g 5mg 5mg15 JAN JAN Erythromycin LactobionateJAN Colistin Sodium MethanesulfonateJAN 1970 3 31 1970 8 1 1970 7 20 TEL0120-921-839 06-6321-7056 9 17 https://www.santen.co.jp/medical/admin/a300.jsp
356 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -/0-0+ (,**1) 44 For Quality Control and Quality Assurance in Food Analysis Akemi Yasui Analyt
356 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -/0-0 (,**1) 44 For Quality Control and Quality Assurance in Food Analysis Akemi Yasui Analytical Science Division, National Food Research Institute,
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
橡14yoshi
8~9 GSI 5cm 35.8g16.7~58.2g 63.0g20.7~124.2g 61.4g20.4 ~102.2g 17 GSI 1.1 0~5.2 4.0 0~17.7 1.9 0~9.6 1.2 0~4.5 0.60~2.6 0.50~2.2 67 66 76 60 3 9.5~27.5 8.9g1.7~9.6 3.6g1.3~6.3 5.3g 2.0~9.2 4.6g 2.1~8.1
untitled
26 3 31 BDF BDF BDF FAME BDF BDF BDF BDF BDF BDF BDF BDF BDF FAME BDF BDF 80.0 97.0% BDF 120 330 0.8% 2.2% 1. 1 1-1 1 1-2 1 2. 2 2-1 2 2-2 5 2-3 6 3. BDF 7 3-1 7 3-2 7 3-3 14 3-4 JOY 21 3-5 32 3-6 39 3-7
27 2 17 学 説 試 験 問 題 (B) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 Na + 2 K 3 kg mg/kg AUC. g/hr/m. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg. 4 Na + -K + -ATPase 5 a b c d e a, b a, e b,
ネオマファーム施工標準軸組構造
注 1 注 2 注 2 SISI 1. 2. 30 35 40 50 15mm 303 (17kg/) 455 16mm, 18mm 250 (20kg/) 455 303 303 _ 6 455 650 10,465 910 2,730 1,820 1,820 910 2,275 1,365 415 450 650
<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
CHEMOTHERAPY SEPT. 1991
CHEMOTHERAPY SEPT. 1991 VOL. 39 S-3 Table 1. Background of characteristics and allocation of 9 healthy male volunteers in a single-dose study on betamipron Table 2. Background of characteristics and allocation
1
0 1 http://barrierfree.nict.go.jp/accessibility/index.html ( ) http://www.soumu.go.jp/joho_tsusin/w_access/index.html JIS X 8341-3 JISC JIS http://www.jisc 2 3 JIS X 8341-3 5.2e 1-62e) JIS X 8341-3 5.2e
橡96-01.PDF
1 961 31 CAS 71432 C 6 H 6 78.11 1) 99 % 1. 5.5 2) 80.1 2) -11 3) 293563 3) 1.48.0% 3) d 20 0.8786 4) 2.77 ( = 1) 4) 4 13.33 kpa (100 mmhg) (26.9) 2) log Pow2.13 ( ) 5) 2.14 ( ) 6) m/z78 ( 1.0 )77 ( 0.20
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
Research and Development Center 1 2
Research and Development Center 1 2 3 4 6 5 6 10 OWER ON OFF TABLE FAN AUTO U AUTO MANU DOWN MANU 100mm 7 8 200ml 3 9 10 11 12 13 14 6 A B C M D E F M Q Q Q E M FC 15 16 M FC FC M M FC FC FC M M M 17 18
<90CE90EC88E290D55F955C8E862E656336>
5 5 9 9 7 7 5 5 6 6 7 7 8 8 9 9 8 8 8 8 79 79 78 78 76 76 77 77 7 7 6 7 7 5 68 68 67 67 66 66 65 65 6 6 6 6 6 6 6 6 6 6 59 59 58 58 57 57 56 56 55 55 5 5 8 8 5 5 9 9 9 8 7 9 9 8 8 7 7 6 6 5 5 5 5 69 69
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)
<4D F736F F D F90858C6E5F C B B B838B>
Isobutyl alcohol IUPAC 2-methylpropan-1-ol 2--1-2-Methyl-1-Propanol, Isobutanol CH 3 H 3 C OH CAS 78-83-1 C 4 H 10 O log P ow ( C) ( C) (kpa) (g/l) 74.12 74.14 1) -108 2) 108 2) 1.2 2) 87 2) 0.8 2) (74.1214)
1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames
資料２
OECD GLP OECD OECD 1960 30 OECD TG 2001 10 17 8 TG 202 208 TG 201 1984 6 TG 202 1984 4 TG 202 2000 10 TG 203 1992 7 TG 204 14 1984 4 TG 205 1984 4 TG 206 1984 4 TG 207 1984 4 TG 208 1984 4 2000 TG 209
http://www.who.int/ipcs/publications/ehc/en/index.html EHC 1 2 3 4 / EHC http://www.nihs.go.jp/dcbi/publist/ehchsg/ 1-8) WHO/IPCS CICAD (Concise Inter
3 [ ] Priority IARC JMPR 2004 10 Priority 1 Priority 1 Priority 2 Priority 3 Priority 1 1-1) CERI) http://www.cerij.or.jp/ceri_jp/koukai/sheet/sheet_indx4.htm http://www.safe.nite.go.jp/data/sougou/pk_list.html?table_name=hyoka&rank=sh
untitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
４ 小川／小川
B p p B pp M p T p M p Tp T pt T p T p T p p Tp T T p T p T pt p Tp p p p p p p p p T p p T T M M p p p p p p T p p p T T p T B T T p T T p T p T T T p T p p T p Tp T p p Tp T p T Tp T T p T p T p T p
グリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
< 別紙 1: 検査値等略称 > 略称 名称 A/G 比 アルブミン / グロブリン比 ADI 一日摂取許容量 ALT アラニンアミノトランスフェラーゼ ATPase adenosine triphosphatase アデノシントリフォスファターゼ AUC 血中薬物濃度 時間曲線下面積 Cmax E
< 別紙 1: 検査値等略称 > 略称 名称 A/G 比 アルブミン / グロブリン比 ADI 一日摂取許容量 ALT アラニンアミノトランスフェラーゼ ATPase adenosine triphosphatase アデノシントリフォスファターゼ AUC 血中薬物濃度 時間曲線下面積 Cmax ECL ELISA EMEA FPIA GC/MS Glu 最高濃度 Enterochromaffin-like